Wall Street analysts expect Acasti Pharma Inc (NASDAQ:ACST) to announce earnings of ($0.09) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Acasti Pharma’s earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.12). Acasti Pharma posted earnings per share of ($0.17) in the same quarter last year, which would indicate a positive year-over-year growth rate of 47.1%. The company is scheduled to issue its next earnings report on Wednesday, June 24th.

On average, analysts expect that Acasti Pharma will report full-year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.62) to ($0.59). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.45) to ($0.03). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Acasti Pharma.

A number of research firms have weighed in on ACST. ValuEngine raised Acasti Pharma from a “hold” rating to a “buy” rating in a research report on Friday, March 13th. HC Wainwright reduced their price target on Acasti Pharma from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, February 18th. Zacks Investment Research downgraded Acasti Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, February 20th. Finally, Aegis dropped their price objective on Acasti Pharma from $3.00 to $2.15 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $3.95.

Shares of ACST opened at $0.65 on Friday. The stock has a 50 day simple moving average of $0.54 and a 200 day simple moving average of $1.12. Acasti Pharma has a 52-week low of $0.25 and a 52-week high of $3.08. The firm has a market capitalization of $57.73 million, a PE ratio of -0.95 and a beta of 2.12.

A number of hedge funds and other institutional investors have recently modified their holdings of ACST. Captrust Financial Advisors acquired a new stake in shares of Acasti Pharma during the 4th quarter worth $48,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Acasti Pharma during the 4th quarter worth $71,000. Oppenheimer & Co. Inc. grew its holdings in shares of Acasti Pharma by 166.4% during the 1st quarter. Oppenheimer & Co. Inc. now owns 198,389 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 123,932 shares in the last quarter. Huber Financial Advisors LLC acquired a new stake in shares of Acasti Pharma during the 4th quarter worth $98,000. Finally, Sargent Investment Group LLC acquired a new stake in shares of Acasti Pharma during the 4th quarter worth $154,000. 5.87% of the stock is currently owned by hedge funds and other institutional investors.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Recommended Story: Short Selling Stocks and Day Traders

Get a free copy of the Zacks research report on Acasti Pharma (ACST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.